At Johnson & Johnson Innovation, we seek to positively impact human health through innovation. As part of our goal, we are pleased to continue our new series called “The Exchange,” where we highlight our leaders and partners who are merging science and collaboration to improve people’s lives around the world.
At Johnson & Johnson Innovation, our oncology experts have a single focus: the elimination of cancer. When pursuing this goal, we find it crucial to bring together the greatest minds and harness their collective expertise in pharmaceuticals, medtech and consumer health. That is why we’re always looking for entrepreneurs and innovators with technologies that make for promising opportunities to potentially create better health outcomes for people with cancer around the world.
To hear more, we recently spoke with Dr. Stefan Hart, Senior Director of Oncology Scientific Innovation at Johnson & Johnson Innovation, Asia Pacific, to discuss the types of solutions Johnson & Johnson Innovation are looking for across Asia Pacific.
Q: Briefly tell us about your role.
A: As the scientific innovation lead for oncology at Johnson & Johnson Innovation, I am responsible for identifying disruptive external innovation in Asia that support oncology strategies for Johnson & Johnson Innovation, Asia Pacific, and Janssen R&D, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Q: What innovative solutions are you seeking from potential partners focused on oncology?
A: One of our long-term goals is to turn cancer into a disease that is preventable, manageable, and curable. To do this, we concentrate our efforts on accelerating solutions that have high-need, compelling science, and high potential to create longer, healthier lives for patients. Our strategic areas in oncology focus on hematologic malignancies, prostate cancer, colorectal cancer, immune therapy, solid tumor targeted therapy and oncology data science.
Q: How will these solutions impact cancer patients in Asia Pacific and the world?
A: In 2020, there was an estimated 19.3 million new cancer cases around the world, nearly half of which were in Asia, proving a greater need to discover innovative solutions for this population. Furthermore, an increasing number of biotech companies are running oncology trials in Asia Pacific, strengthening the region’s reputation for oncology drug development. We hope that these new efforts will improve the lives of people with cancer in Asia Pacific and the world and that they will ultimately contribute to the elimination of cancer entirely.
Q: Why should innovators partner with Johnson & Johnson?
A: At Johnson & Johnson Innovation, we truly believe that a great idea can come from anywhere and we are proud of the progress we’ve made in sourcing novel and potentially transformational early-stage healthcare innovations. With integrated teams across the region based in Shanghai, Tokyo, Seoul, Singapore and Hong Kong, Johnson & Johnson Innovation makes it easy for our collaborators and strategic partners to tap into our broad range of tools and capabilities, no matter where an idea is in its life cycle. Through these collaborations, we can address some of the world’s toughest healthcare challenges, and we invite all oncology-focused innovators and entrepreneurs to contact us.
Q: What kind of partners excite you the most?
A: No single company can solve the challenges of cancer alone, so we seek to connect any innovators or entrepreneurs with bright ideas in science and technology to our global network of resources, tools, and expertise to help bring transformational therapies to patients who previously had few or no options. Currently in Asia Pacific, we’re focused on working with innovators developing potentially transformative technologies like CAR-T therapy, T cell redirection, ADC, and more.
To learn more about immuno-oncology and partnering with Johnson & Johnson Innovation, we encourage you to join our immuno-oncology webinar on June 23 from 8:30am-9:30am (GMT +8) and apply for a 1:1 meeting if you have a transformational idea in oncology.
If you are based in the Asia Pacific and would like to connect with us on other therapeutic areas, reach out to our
Regional Sourcing Leader, Charleen Nien at firstname.lastname@example.org
 “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, 2021, doi.org/10.3322/caac.21660.